Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability of Fipravirimat/Dolutegravir FDC in Healthy Participants
NCT04857892Phase 1Completed
- Sponsor
- ViiV Healthcare
- Start
- Apr 2021
- Primary completion
- Sep 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of fipravirimat in human immunodeficiency virus infection (HIV) (5 arms), sponsored by ViiV Healthcare. Primary endpoints: Area Under the Plasma Concentration-time Curve From Time 0 Extrapolated to Infinity, Area Under the Plasma Concentration-time Curve From Time 0 to Time t and 1 more. Started Apr 2021; status: completed.
02
Drugs
fipravirimat
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT04857892.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04857892.